Return to study ST000138 main page
MB Sample ID: SA007599
Local Sample ID: | PF0246 |
Subject ID: | SU000157 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR000159 |
Treatment Summary: | Atenolol was initiated at 50mg, and titrated to 100mg, based on BP > 120/70 mmHg and tolerability. Blood samples were collected prior to initiation of atenolol treatment and after at least 6 weeks on the final dose. Blood samples were spun and serum and plasma fractions stored at -80C. Treatment: Intervention Treatment Compound: Atenolol Treatment Dose: 50mg titrated to 100mg based on BP and tolerability Treatment Dose Duration: Minimum of 6 weeks |